Logo image of KRON

KRONOS BIO INC (KRON) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KRON - US50107A1043 - Common Stock

0.88 USD
+0.01 (+1.49%)
Last: 6/20/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, KRON scores 3 out of 10 in our fundamental rating. KRON was compared to 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KRON as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, KRON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KRON has reported negative net income.
KRON had a negative operating cash flow in the past year.
In the past 5 years KRON always reported negative net income.
In the past 5 years KRON always reported negative operating cash flow.
KRON Yearly Net Income VS EBIT VS OCF VS FCFKRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

KRON has a Return On Assets (-59.63%) which is in line with its industry peers.
The Return On Equity of KRON (-80.80%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -59.63%
ROE -80.8%
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-44.62%
ROE(3y)-74.53%
ROE(5y)-57.27%
ROIC(3y)N/A
ROIC(5y)N/A
KRON Yearly ROA, ROE, ROICKRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KRON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRON Yearly Profit, Operating, Gross MarginsKRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

KRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KRON has been increased compared to 1 year ago.
KRON has more shares outstanding than it did 5 years ago.
KRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KRON Yearly Shares OutstandingKRON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KRON Yearly Total Debt VS Total AssetsKRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

KRON has an Altman-Z score of -7.09. This is a bad value and indicates that KRON is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.09, KRON is not doing good in the industry: 67.74% of the companies in the same industry are doing better.
There is no outstanding debt for KRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.09
ROIC/WACCN/A
WACC8.93%
KRON Yearly LT Debt VS Equity VS FCFKRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

KRON has a Current Ratio of 12.93. This indicates that KRON is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of KRON (12.93) is better than 84.77% of its industry peers.
A Quick Ratio of 12.93 indicates that KRON has no problem at all paying its short term obligations.
The Quick ratio of KRON (12.93) is better than 84.77% of its industry peers.
Industry RankSector Rank
Current Ratio 12.93
Quick Ratio 12.93
KRON Yearly Current Assets VS Current LiabilitesKRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

KRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.50%, which is quite impressive.
Looking at the last year, KRON shows a very strong growth in Revenue. The Revenue has grown by 21.17%.
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.66%
Revenue 1Y (TTM)21.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-26.03%

3.2 Future

The Earnings Per Share is expected to decrease by -1.90% on average over the next years.
KRON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 47.58% yearly.
EPS Next Y0%
EPS Next 2Y-1.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y14.47%
Revenue Next 5Y47.58%

3.3 Evolution

KRON Yearly Revenue VS EstimatesKRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
KRON Yearly EPS VS EstimatesKRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KRON. In the last year negative earnings were reported.
Also next year KRON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRON Price Earnings VS Forward Price EarningsKRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRON Per share dataKRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.9%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KRONOS BIO INC

NASDAQ:KRON (6/20/2025, 8:00:02 PM)

0.88

+0.01 (+1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners29.29%
Inst Owner Change-85.35%
Ins Owners6.07%
Ins Owner Change-4.88%
Market Cap53.65M
Revenue(TTM)9.19M
Net Income(TTM)-64.48M
Analysts82.86
Price Target2.3 (161.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)18.34%
Min Revenue beat(2)-9.53%
Max Revenue beat(2)46.2%
Revenue beat(4)3
Avg Revenue beat(4)30.02%
Min Revenue beat(4)-9.53%
Max Revenue beat(4)72.75%
Revenue beat(8)6
Avg Revenue beat(8)35.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.84
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-1.07
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.15
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.63%
ROE -80.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-44.62%
ROE(3y)-74.53%
ROE(5y)-57.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.21%
Cap/Sales 0.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.93
Quick Ratio 12.93
Altman-Z -7.09
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)19.19%
Cap/Depr(5y)282.4%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.66%
EPS Next Y0%
EPS Next 2Y-1.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)21.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-26.03%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y14.47%
Revenue Next 5Y47.58%
EBIT growth 1Y53.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.92%
OCF growth 3YN/A
OCF growth 5YN/A

KRONOS BIO INC / KRON FAQ

What is the fundamental rating for KRON stock?

ChartMill assigns a fundamental rating of 3 / 10 to KRON.


What is the valuation status for KRON stock?

ChartMill assigns a valuation rating of 0 / 10 to KRONOS BIO INC (KRON). This can be considered as Overvalued.


What is the profitability of KRON stock?

KRONOS BIO INC (KRON) has a profitability rating of 1 / 10.